Microchip Restores Vision

A wirelessly controlled microchip has restored limited vision to patients in a small experimental trial, report researchers in the Proceedings of the Royal Society B.

The German medical technology company Retina Implant developed the artificial retina, which was implanted in one eye of each participant as part of a company-funded trial. The patients had all been blinded by retinitis pigmentosa or another inherited disease that cause the eye’s light-detecting rod and cone cells, called photoreceptors, to degenerate and die over time. In theory, the device could also benefit patients with degenerative eye diseases such as macular degeneration, says Katarina Štigl, a clinical scientist and ophthalmologist at the University of Tübingen, who led the study.

With the implant, eight of the nine patients in the trial could perceive light. Five were able to detect moving patterns on a screen as well as everyday objects such as cutlery, doorknobs, and telephones. Three were able to read letters. Seeing their own hands and the faces of their loved ones had the biggest impression on the patients, says Štigl. “The very personal things, such as if a mouth is smiling, or the shape of a nose, are the most exciting for them,” she says.

The implanted device consists of a three-millimeter-square chip with 1,500 pixels. Each pixel contains a photodiode, which picks up incoming light, and an electrode and an amplification circuit, which boosts the weak electrical activity given off by the diode. A thin cable that runs through the eye socket connects the implant to a small coil implanted under the skin behind the ear, which means most of the system is invisible. The coil under the skin is powered by an external battery pack that can be held behind the ear with magnets.

The results follow an announcement earlier this week from California-based Second Sight that its Argus II system was approved for use in the United States. The two technologies take different approaches to restoring vision in patients with retinal degeneration. In Second Sight’s system, a camera mounted on eyeglasses picks up images that are converted into electrical signals by a small wearable computer. That data is then sent to a 60-electrode chip to stimulate neurons in the retina. The Retina Implant device instead attempts to directly replace the lost photoreceptors, allowing the remaining retinal circuitry to do the data processing.

Researchers at the University of Illinois at Urbana-Champaign and Tufts University say they have invented functional electronic implants that can dissolve after programmable time periods. To demonstrate the system, which could aid in healing during the first few crucial days after an operation, they implanted one in a rat. It created a temporary temperature increase to sterilize a wound, and then it dissolved after 15 days. The researchers reported the development this week in the journal Science.

Biomedical researchers are turning to the idea of “programmable degradation” because it is difficult to develop materials that remain compatible with human tissue over the long term. Medical implants or drug-delivery systems that do their work and then disappear are ideal. To develop the electronic implants, the researchers encased them in silk. That material’s characteristics, particularly its crystallinity, can be adjusted so that its degradation time can be anywhere from seconds to years.

The electronics inside the silk were based on nanometers-thick sheets or ribbons of silicon, called silicon nanomembranes. The materials have been previously used to make experimental transistors, diodes, complementary logic devices, and photocells for flexible surfaces. Whereas a conventional silicon wafer or a chip would take about a thousand years to dissolve in biofluids, says John A. Rogers, who led the research at the University of Illinois, a nanomembrane is gone in a couple of weeks.